scispace - formally typeset
Search or ask a question

Showing papers by "Marguerite Ennis published in 2007"

Journal Article•DOI•
Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer

[...]

Anna Marie Mulligan1, Anna Marie Mulligan2, Frances P. O'Malley1, Frances P. O'Malley2, Marguerite Ennis, I. George Fantus1, I. George Fantus2, Pamela J. Goodwin1, Pamela J. Goodwin2 •
Mount Sinai Hospital1, University of Toronto2
13 Jan 2007-Breast Cancer Research and Treatment
TL;DR: High expression of IR is independently and significantly associated with more favorable clinical outcomes and follow-up intervention research is recommended.
Abstract: Fasting insulin is related to outcome in early breast cancer. We evaluated the expression of insulin receptor (IR) and its prognostic significance in patients with early stage breast cancer. Tumors from 191 patients with T1-3, N0-1, M0 breast cancer who were enrolled at a single center of a multicenter cohort study were used to construct microarrays with subsequent immunohistochemical evaluation of IR, IGF-IR, ER, PgR and HER2/neu. Correlation of biomarker expression with traditional prognostic factors, serum biochemistry (notably insulin) and clinical outcome was assessed. IR was strongly positive (Allred score = 8) in 54% of tumors. High IR expression significantly correlated with favorable prognostic markers (low tumor grade, lymph node negativity and progesterone receptor positivity) but not with fasting levels of circulating insulin. At a median follow-up of 9.1 years, high vs. low IR expression (an Allred score of 8 vs. 0-7) was associated with statistically significant improved distant disease-free survival (multivariate hazard ratio (HR) = 0.4; P = 0.027) and overall survival (multivariate HR = 0.26; P = 0.005). IR is highly expressed in the majority of early stage breast cancers but this expression is not clearly down-regulated in the presence of high insulin levels. Furthermore, high expression of IR is independently and significantly associated with more favorable clinical outcomes. Follow-up intervention research is recommended.

96 citations

Journal Article•DOI•
Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

[...]

Jane C. Figueiredo1, Jane C. Figueiredo2, Marguerite Ennis, Julia A. Knight2, Julia A. Knight1, John R. McLaughlin3, John R. McLaughlin2, John R. McLaughlin1, Nicky Hood4, Frances P. O'Malley2, Frances P. O'Malley1, Irene L. Andrulis1, Irene L. Andrulis2, Irene L. Andrulis3, Pamela J. Goodwin2, Pamela J. Goodwin1 •
Mount Sinai Hospital1, University of Toronto2, Cancer Care Ontario3, Mount Sinai Hospital, Toronto4
01 Sep 2007-Breast Cancer Research and Treatment
TL;DR: Women diagnosed with BC at age ≤35 have more aggressive tumors; these adverse tumor characteristics, rather than age, lead to poor outcomes, which are restricted to younger women with hormone responsive BC.
Abstract: Purpose The objective of this study was to examine the association of: (i) diagnosis at age ≤35, (ii) first-degree family history of breast or ovarian cancer (BOC) and (iii) a research based definition of genetic risk, with tumor characteristics, treatment and survival in breast cancer (BC).

64 citations